Navigation Links
IPC The Hospitalist Company, Inc. Reaffirms Guidance for 2008
Date:6/17/2008

NORTH HOLLYWOOD, Calif., June 17 /PRNewswire-FirstCall/ -- IPC The Hospitalist Company, Inc. (Nasdaq: IPCM), a leading national hospitalist physician group practice, today reaffirmed its guidance for full year 2008 revenue to be in the range of $239 million to $245 million and full year 2008 earnings per adjusted pro-forma fully diluted share (excluding bonuses incurred in the first quarter related to the Company's IPO) to be in the range of $0.87 to $0.94. Absent the impact of acquisitions, the Company typically experiences a pattern of seasonality with net revenue and earnings in the first and fourth quarters of the year higher than those in the second and third quarters. The Company expects this pattern to continue and believes it is primarily due to the following factors:

-- the number of physicians the Company has on staff during the quarter,

which may fluctuate based upon the timing of hires caused by the end of

the academic year for graduating resident physicians and the schedule

of the Internal Medicine Board exams and terminations in our existing

practices; and

-- fluctuations in patient encounters which are impacted by hospital

census and physician productivity and often reflect seasonality due to

the higher occurrence of such illnesses as flu and pneumonia in patient

populations in the first quarter.

This guidance does not include new market acquisitions. The Company undertakes no obligation following the date of this press release to update or revise any such statements or projections whether as a result of new information, future events, or otherwise.

Reconciliation for Non-GAAP Financial Measures

The Company's Board of Directors approved one-time bonuses paid in the first quarter of 2008 related to the Company's IPO of $0.3 million, which decreased the Company's pro-forma fully diluted earnings per share for the first quarter of 2008 by $0.01. IPC computes its adjusted pro-forma fully diluted earnings per share excluding these one-time bonuses to reflect its on-going operations. IPC's management believes that while excluding the one-time bonuses from the calculation of pro-forma fully diluted earnings per share is considered a non-GAAP measure, it more clearly depicts the operating performance of the Company and enables more appropriate period-to-period measures. However, adjusted pro-forma fully diluted earnings per share is a non-GAAP measure and thus should not be used as a substitute for pro-forma fully diluted earnings per share.

The Company's guidance for 2008 is based upon assumptions that the Company's management believes reasonable, but there can be no assurance that these future results will be achieved.

About IPC The Hospitalist Company

IPC The Hospitalist Company, Inc. (Nasdaq: IPCM) is a leading national physician group practice company focused on the delivery of hospitalist medicine services. IPC's physicians and affiliated providers manage the care of hospitalized patients in coordination with primary care physicians and specialists. The Company provides its hospitalists with the comprehensive training, information technology, and management support systems necessary to improve the quality and reduce the cost of inpatient care in the facilities it serves. For more information, visit the IPC website at http://www.hospitalist.com.

Safe Harbor Statement

Certain statements and information in this press release may be deemed to be "forward-looking statements" within the meaning of the Federal Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release may include, but are not limited to, those statements set forth above regarding projected operating results, revenues, earnings and seasonality. Forward-looking statements are often characterized by terminology such as "believe", "hope", "may", "anticipate", "should", "intend", "plan", "will", "expect", "estimate", "project", "positioned", "strategy" and similar expressions. Any forward-looking statements are necessarily based on a variety of estimates and assumptions which, though considered reasonable by the Company, may not be realized and are inherently subject to significant business, economic, competitive, industry, regulatory, market and financial uncertainties and contingencies, many of which are and will be beyond IPC's control. Important risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by any forward-looking statements are described in IPC's most recent Annual Report on Form 10-K, including the section titled "Risk Factors," and actual results could differ materially from those anticipated in forward-looking statements.

In particular the following risks and uncertainties may have such an impact:

-- failure to comply with complex and intensive government regulation of

our industry;

-- the ability of our affiliated hospitalists to appropriately document

services they provide;

-- the adequacy of our insurance coverage and insurance reserves;

-- our ability to recruit and retain qualified physicians;

-- our ability to successfully integrate new acquisitions;

-- the effect of changes in rates or methods of third-party reimbursement;

and

-- the high level of competition in our industry.

IPC undertakes no obligation following the date of this press release to update or revise any such statements or projections whether as a result of new information, future events, or otherwise.

This press release contains non-GAAP financial measures. For reconciliations of these non-GAAP financial measures to their most recent comparable measure calculated and presented in accordance with GAAP, see "Reconciliation for Non-GAAP Financial Measures," above.

Contacts:

Devra Shapiro Stephanie Carrington/Jared Hoffman

IPC The Hospitalist Company, Inc. The Ruth Group

(818) 766-3502 646-536-7017/7013

scarrington@theruthgroup.com

jhoffman@theruthgroup.com


'/>"/>
SOURCE IPC The Hospitalist Company, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
2. Inverness Medical Innovations to Present at 7th Annual Needham & Company, LLC Biotechnology & Medical Technology Conference on June 12, 2008
3. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
4. Takedas Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
5. Amnis and Gene Company, Ltd. Announce Agreement to Market ImageStream Technology in China
6. Pathology Consultants, Inc. Selects PSA, LLC, a MED3OOO Company, as Their Business Partner
7. InnovationRx, a Prescription Adherence Solutions Company, and InforMedix Partner to Market and Sell End-to-End Medication Adherence Solutions
8. China Aoxing Pharmaceutical Company Signed Definitive Acquisition Agreement to Acquire Shijiazhuang Lerentang Pharmaceutical Company, Ltd.
9. The Jordan Company, L.P. Has Teamed with the Management of Haas TCM Inc. to Form Haas TCM Group Inc.
10. Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance
11. Study Reaffirms Superiority of Trofile(TM) Assay
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... N.Y. , Dec. 2, 2016 More than ... (CSHL) 11th Double Helix Medals dinner ( DHMD ). The gala was ... New York City and honored ... their contributions, respectively, to health and medicine and the public ... Ali in 2006, the event has raised $40 million ...
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... ACEA Biosciences, ... its Phase I/II clinical trials for AC0010 at the World Conference on Lung Cancer ... providing an update on the phase I/II clinical trials for AC0010 in patients with ...
(Date:12/2/2016)... ... , ... DrugDev believes the only way to achieve real change ... three tenets were on display at the 2nd Annual DrugDev User Summit (hosted by ... and site organizations to discuss innovation and the future of clinical research. , ...
(Date:12/2/2016)... 2, 2016 The immunohistochemistry (IHC) market ... a CAGR of 7.3% during the forecast period of 2016 to ... laboratories segment accounted for the largest share of immunohistochemistry (IHC) market, ... , ... immunohistochemistry (IHC) market spread across 225 pages, profiling 10 companies and ...
Breaking Biology Technology:
(Date:6/22/2016)... -- The American College of Medical Genetics and Genomics was once ... one of the fastest-growing trade shows during the Fastest 50 ... Las Vegas . Winners ... each of the following categories: net square feet of paid ... The 2015 ACMG Annual Meeting was ranked 23 out of ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/9/2016)... -- Paris Police Prefecture ... to ensure the safety of people and operations in several ... tournament Teleste, an international technology group specialised in ... that its video security solution will be utilised by ... safety across the country. The system roll-out is scheduled for ...
Breaking Biology News(10 mins):